Skip to content

Confocal Laser Endomicroscopy With Cresyl Violet for in Vivo Diagnosis of Gastric Intestinal Metaplasia

Cresyl Violet as a New Contrast Agent in Confocal Laser Endomicroscopy for in Vivo Diagnosis of Gastric Intestinal Metaplasia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03672708
Enrollment
48
Registered
2018-09-14
Start date
2018-09-16
Completion date
2019-01-02
Last updated
2019-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Intestinal Metaplasia

Brief summary

Confocal laser endomicroscopy (CLE) is a novel endoscopic system which can provide approximately 1000-fold magnification of the gastrointestinal mucosa. Previous studies have demonstrated its diagnostic value for Gastric intestinal metaplasia (GIM) with the use of a contrast agent.Recently, Cresyl violet (CV) has been used in CLE to visualize tissue architecture in human ileum, colon or myenteric plexus.No investigation has reported the characterization of GIM imaged with CLE when using CV as staining dye

Interventions

DIAGNOSTIC_TESTCresyl violet

cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE

Sponsors

Shandong University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients who had long-lasting upper gastrointestinal symptoms and aged 40 years or above * patients with H. pylori infection, or known GIM or atrophic gastritis

Exclusion criteria

* patients with a history of GI surgery * advanced gastric carcinoma or any other malignancy in the GI tract * acute upper GI bleeding * patients with contraindications to CLE examination, such as coagulopathy, pregnancy, breast feeding, impaired renal or liver function * patients refused to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
feasibility of CV for identifying GIM1 monthratio of pCLE failure to visualize the cellular and subcellular structures
newly pCLE criteria with CV application for GIM1 monthratio of diagnostic agreement between pCLE using CV and histopathological results

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026